Trial‐based cost‐effectiveness analysis of Descemet membrane endothelial keratoplasty (<scp>DMEK</scp>) versus ultrathin Descemet stripping automated endothelial keratoplasty (<scp>UT‐DSAEK</scp>)

Abstract

The base case cost-effectiveness analysis favoured UT-DSAEK over DMEK, as costs of DMEK were higher while QALYs were lower. Further studies are required to assess long-term rebubbling and regraft rates and graft survival.